- Home
- BRN vs EQ Comparison
BRN vs EQ Comparison
Compare BRN & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRN
- EQ
- Stock Information
- Founded
- BRN 1956
- EQ 2017
- Country
- BRN United States
- EQ United States
- Employees
- BRN N/A
- EQ N/A
- Industry
- BRN Oil & Gas Production
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- BRN Energy
- EQ Health Care
- Exchange
- BRN Nasdaq
- EQ Nasdaq
- Market Cap
- BRN 13.9M
- EQ 12.2M
- IPO Year
- BRN N/A
- EQ 2018
- Fundamental
- Price
- BRN $1.16
- EQ $0.42
- Analyst Decision
- BRN
- EQ Buy
- Analyst Count
- BRN 0
- EQ 3
- Target Price
- BRN N/A
- EQ $3.00
- AVG Volume (30 Days)
- BRN 99.3K
- EQ 544.3K
- Earning Date
- BRN 08-12-2025
- EQ 08-07-2025
- Dividend Yield
- BRN N/A
- EQ N/A
- EPS Growth
- BRN N/A
- EQ N/A
- EPS
- BRN N/A
- EQ N/A
- Revenue
- BRN $19,387,000.00
- EQ $30,406,000.00
- Revenue This Year
- BRN N/A
- EQ N/A
- Revenue Next Year
- BRN N/A
- EQ N/A
- P/E Ratio
- BRN N/A
- EQ N/A
- Revenue Growth
- BRN N/A
- EQ N/A
- 52 Week Low
- BRN $1.08
- EQ $0.27
- 52 Week High
- BRN $2.53
- EQ $1.50
- Technical
- Relative Strength Index (RSI)
- BRN 44.13
- EQ 63.74
- Support Level
- BRN $1.11
- EQ $0.29
- Resistance Level
- BRN $1.25
- EQ $0.45
- Average True Range (ATR)
- BRN 0.07
- EQ 0.05
- MACD
- BRN -0.00
- EQ 0.01
- Stochastic Oscillator
- BRN 43.17
- EQ 65.84
About BRN Barnwell Industries Inc.
Barnwell Industries Inc is an oil and gas firm. Its areas of operations include acquiring, developing, producing, and selling oil and natural gas. The company acquires and develops crude oil and natural gas assets. The company's operating segment includes Oil and natural gas, Contract drilling, Land investment, and Others. It generates maximum revenue from the Oil and natural gas segment. It operates in two geographical segments the United States, which generates a majority of revenue, and Canada.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.